Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis.

Background: For patients with MS, medication switches increase the risk of disease reactivation.

Objective: Compare discontinuation rates due to treatment failure or side effects between teriflunomide and dimethyl fumarate, and investigate clinical variables affecting discontinuation rates.

Methods: All patients who received teriflunomide or dimethyl fumarate at Haukeland University Hospital from 2013 until 2018 were identified.